Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 9/30
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pharma-Bio Serv's operating cash flow for the twelve months ending Jul 31, 2026 was -$414.89K. For fiscal 2025 it was -$214.89K. The highest annual figure on record is $5.63M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$214.89K | – |
| FY2024 | Oct 31, 2024 | -$566.70K | -130.0% |
| FY2023 | Oct 31, 2023 | $1.89M | +219.2% |
| FY2022 | Oct 31, 2022 | $592.46K | -26.4% |
| FY2021 | Oct 31, 2021 | $804.84K | -46.9% |
| FY2020 | Oct 31, 2020 | $1.51M | – |
| FY2019 | Oct 31, 2019 | -$2.21M | -159.4% |
| FY2018 | Oct 31, 2018 | $3.72M | – |
| FY2017 | Oct 31, 2017 | -$922.67K | -230.0% |
| FY2016 | Oct 31, 2016 | $709.65K | +90.5% |
| FY2015 | Oct 31, 2015 | $372.61K | -88.8% |
| FY2014 | Oct 31, 2014 | $3.33M | -40.8% |
| FY2013 | Oct 31, 2013 | $5.63M | +128.8% |
| FY2012 | Oct 31, 2012 | $2.46M | +14.9% |
| FY2011 | Oct 31, 2011 | $2.14M | +358.9% |
| FY2010 | Oct 31, 2010 | $466.35K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $60.89K | -74.3% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$365.31K | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$390.14K | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $279.67K | +256.6% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $236.52K | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$301.59K | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$429.49K | -159.2% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $78.43K | -74.6% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$670.33K | -170.1% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$700.74K | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $725.95K | -17.1% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $308.44K | -7.2% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $956.77K | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$250.11K | -126.0% |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $875.87K | +98.3% |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | $332.37K | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$1.11M | -288.0% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | $960.35K | +185.5% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $441.72K | -63.8% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | -$1.19M | – |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $588.19K | -61.2% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $336.37K | – |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $1.22M | – |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -$1.56M | – |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $1.52M | – |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -$539.81K | -218.1% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -$627.30K | -137.2% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | -$822.92K | -615.7% |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | -$217.71K | -115.4% |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $456.91K | +63.4% |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $1.69M | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | $159.58K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | $1.42M | +664.3% |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | $279.57K | -39.6% |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$478.40K | -1184.3% |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$909.23K | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | $185.39K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | $463.24K | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | $44.12K | – |
See a number that looks wrong?